$0.40
10.74%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
US00972D1054
Symbol
AKBA

Akebia Therapeutics, Inc. Stock News

Neutral
●
GlobeNewsWire
●
about one hour ago
New patent with term until 2043 further strengthens patent portfolio WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted for Vafseo® (vadadustat), strengthening Akebia's vadadustat intellectual property...
Neutral
●
GlobeNewsWire
●
one day ago
Initial $60 million tranche fully funded, proceeds of which were used to fully repay $55 million BlackRock loan facility
Neutral
●
GlobeNewsWire
●
12 days ago
Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025
Neutral
●
GlobeNewsWire
●
12 days ago
WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced topline results from VOCAL, an open-label trial to evaluate the efficacy and safety of three times per week (TIW) dosing of vadadustat compared to the current standard of care erythropo...
Neutral
●
GlobeNewsWire
●
22 days ago
Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen
Neutral
●
GlobeNewsWire
●
about one month ago
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-...
Neutral
●
GlobeNewsWire
●
about one month ago
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today